文献速递肿瘤 PET/CT

PSMA PET/CT与增强MRI在青少年鼻咽血管纤维瘤随访评估中的比较:一项新型初步研究

Comparison of Prostate-Specific Membrane Antigen PET/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma-A Novel Pilot Study.
PubMed 文献 · Clin Nucl Med · 2020-01-01

这项前瞻性研究纳入18例术后高度怀疑残留的青少年鼻咽血管纤维瘤(JNA)患者,比较PSMA PET/CT与增强MRI诊断残留/复发肿瘤的效能。以手术活检解决不一致病例,PSMA PET/CT的敏感性、特异性、阳性预测值和阴性预测值均为100%,而增强MRI分别为100%、33.33%、75%和100%。PSMA PET/CT在识别残留/复发JNA方面比增强MRI更具特异性。

要点

  • PSMA PET/CT诊断残留/复发JNA的敏感性、特异性、阳性预测值和阴性预测值均为100%。
  • 增强MRI诊断残留/复发的特异性仅33.33%,阳性预测值75%。
  • 4例影像不一致病例经活检均为纤维化,支持PSMA PET/CT判断。

核心结论

  • Ga-PSMA PET/CT在识别残留/复发JNA方面比当前标准增强MRI更具特异性。
  • 这是首个应用于JNA术后评估的放射性核素显像。

研究设计与样本

  • 所有患者接受头颈部spot PSMA PET/CT,影像结果分为阴性、可疑和残留/复发,不一致病例由手术活检解决。

主要发现

  • 增强MRI评估:14/18例有残留肿瘤,2例可疑残留,2例术后扫描正常。
  • PSMA PET/CT评估:12/18例有残留肿瘤,6例阴性。
  • 4例影像不一致病例的手术活检均阴性,仅见纤维化。
  • 1例两扫描均示残留但范围不一致,进一步手术切除证实PSMA PET/CT的影像发现准确。
  • 两种检查间评价者一致性κ值为0.5(95%CI 0.19-0.81)。

关键数值与推荐

  • 增强MRI以明确病灶的对比增强作为残留/复发肿瘤标准。
  • PSMA PET/CT以头颈部生理部位以外的任何异常摄取作为残留病灶标准。
  • 增强MRI敏感性100%、特异性33.33%、阳性预测值75%、阴性预测值100%。
  • PSMA PET/CT敏感性、特异性、阳性预测值和阴性预测值均为100%。

临床怎么用

  • 对于术后随访高度怀疑残留/复发的JNA患者,PSMA PET/CT可较增强MRI更特异地识别残留/复发肿瘤。
  • 影像不一致时可通过手术活检明确诊断。

局限性

  • 研究为初步探索性研究,样本量18例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/BACKGROUND: The specific identification of residual/recurrent juvenile nasal angiofibroma (JNA) following surgical treatment remains difficult. Contrast MRI and CT may not enable the differentiation of tumor from postsurgical reparative tissue. Functional imaging with prostate-specific membrane antigen (PSMA) PET/CT targeting tumor-associated neovasculature has recently demonstrated universal positive uptake in primary JNA and offers promise of greater accuracy in the detection or exclusion of recurrent/residual JNA. METHODS: In this prospective study, 18 postsurgical JNA patients with high suspicion for residual disease evinced by follow-up MR scan, or nasal endoscopy, or recent epistaxis during September 2018-November 2019 were included. All patients underwent head and neck spot PSMA PET/CT imaging. Postcontrast enhancement of a definite lesion was considered as a criterion for residual/recurrent tumor in contrast-enhanced MRI (CEMRI). In PSMA PET/CT, any abnormal uptake apart from physiological sites in the head and neck was considered as residual lesions. Radiological results were categorized as negative, suspicious, and residual/recurrent tumors. Any discrepancy between CEMRI and PSMA was resolved by surgical biopsies. The sensitivity, specificity, and positive and negative predictive values were separately calculated for CEMRI and PSMA PET/CT for diagnosing residual lesions. The interrater agreement κ value was also calculated. RESULTS: On CEMRI evaluation, 14 of 18 patients had residual tumors, 2 had suspicious residual lesions, and 2 had normal postoperative scans. On PSMA PET/CT, 12 of 18 patients had residual tumors, and 6 had normal negative scans. Surgical biopsy in all 4 discordant cases was negative for tumors and revealed only fibrosis. In 1 patient with residual tumor on both scans, discrepancy was noted with regard to tumor extent demonstrated by the 2 scans, and further surgical excision confirmed the imaging findings of PSMA PET/CT as accurate. The sensitivity, specificity, and positive and negative predictive values of CEMRI were 100%, 33.33%, and 75% and 100%, respectively. The sensitivity, specificity, and positive and negative predictive values of PSMA PET/CT were 100% for all parameters. The interrater agreement between the 2 tests (κ) is 0.5 (95% confidence interval, 0.19-0.81). CONCLUSIONS: The Ga-PSMA PET/CT is noted as more specific than the current standard of CEMRI in the identification of residual/recurrent JNA. It is the first radionuclide imaging scan that has found application in postoperative assessment of JNA. TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI/2018/08/015479).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thakar A, Sakthivel P, Arunraj ST, et al. Comparison of Prostate-Specific Membrane Antigen PET/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma-A Novel Pilot Study. Clin Nucl Med. 2020. PMID: 33065615. doi:10.1097/RLU.0000000000003311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。